FY2025 EPS Estimates for TLSI Lowered by Cantor Fitzgerald

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) - Analysts at Cantor Fitzgerald cut their FY2025 earnings per share estimates for TriSalus Life Sciences in a research note issued on Monday, May 19th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will post earnings of ($0.90) per share for the year, down from their prior estimate of ($0.56). The consensus estimate for TriSalus Life Sciences' current full-year earnings is ($1.55) per share.

Other equities analysts have also recently issued reports about the stock. Canaccord Genuity Group reiterated a "buy" rating and set a $11.00 price objective on shares of TriSalus Life Sciences in a research report on Friday, March 28th. Lake Street Capital assumed coverage on TriSalus Life Sciences in a report on Thursday, February 13th. They set a "buy" rating and a $10.00 target price on the stock. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $10.93.

TriSalus Life Sciences Stock Up 3.9%

NASDAQ TLSI traded up $0.21 on Wednesday, reaching $5.56. 48,238 shares of the stock traded hands, compared to its average volume of 42,285. TriSalus Life Sciences has a 12 month low of $3.50 and a 12 month high of $7.90. The company has a market cap of $179.43 million, a price-to-earnings ratio of -2.23 and a beta of 0.50. The firm's fifty day simple moving average is $5.42 and its 200 day simple moving average is $5.05.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.13). The firm had revenue of $9.17 million during the quarter, compared to analyst estimates of $9.04 million. During the same quarter last year, the firm earned ($0.60) EPS.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC lifted its stake in shares of TriSalus Life Sciences by 1.9% in the fourth quarter. Geode Capital Management LLC now owns 204,137 shares of the company's stock valued at $1,023,000 after buying an additional 3,710 shares in the last quarter. Northern Trust Corp grew its position in TriSalus Life Sciences by 22.7% during the fourth quarter. Northern Trust Corp now owns 32,112 shares of the company's stock valued at $161,000 after buying an additional 5,936 shares during the period. Charles Schwab Investment Management Inc. purchased a new stake in shares of TriSalus Life Sciences during the 1st quarter worth approximately $55,000. Renaissance Technologies LLC bought a new stake in shares of TriSalus Life Sciences in the fourth quarter valued at $67,000. Finally, Connective Capital Management LLC purchased a new stake in TriSalus Life Sciences during the fourth quarter valued at about $140,000. 2.58% of the stock is owned by institutional investors.

Insider Activity at TriSalus Life Sciences

In related news, insider Richard Marshak sold 6,597 shares of the stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $5.18, for a total transaction of $34,172.46. Following the sale, the insider now owns 69,101 shares in the company, valued at approximately $357,943.18. This trade represents a 8.71% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last ninety days, insiders sold 16,125 shares of company stock valued at $83,528. Insiders own 27.50% of the company's stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.